Answers are grounded in this paper and cite their sources.
without disrupting beneficial flora. Clinical trials have demonstrated significant reductions in inflammatory lesions and improved quality-of-life metrics in patients receiving these microbiota-targeted treatments. This review synthesizes current evidence on the bidirectional interplay between metabolic disorders and skin microbiota, highlighting therapeutic implications and future directions. By addressing systemic metabolic dysfunction and microbiota-mediated pathways, precision strategies are paving the way for improved patient outcomes in dermatologic care.
No takes yet. Share an insight, caveat, or question.
Kreouzi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: